Anne Nunes Net Worth

The estimated Net Worth of Anne Nunes is at least $287 ezer dollars as of 11 March 2024. Ms Nunes owns over 5,856 units of Anika Therapeutics stock worth over $287,072 and over the last few years she sold ANIK stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Nunes ANIK stock SEC Form 4 insiders trading

Ms has made over 2 trades of the Anika Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently she exercised 5,856 units of ANIK stock worth $142,008 on 11 March 2024.

The largest trade she's ever made was exercising 5,856 units of Anika Therapeutics stock on 11 March 2024 worth over $142,008. On average, Ms trades about 2,782 units every 54 days since 2023. As of 11 March 2024 she still owns at least 11,838 units of Anika Therapeutics stock.

You can see the complete history of Ms Nunes stock trades at the bottom of the page.

Ms. Anne Nunes biography

Anne Nunes is the VP of Operations at Anika Therapeutics.

Insiders trading at Anika Therapeutics

Over the last 21 years, insiders at Anika Therapeutics have traded over $58,649,775 worth of Anika Therapeutics stock and bought 34,227 units worth $758,329 . The most active insiders traders include Charles H Sherwood, Farmaceutici S.P.A. Fidia és Joseph H Capper. On average, Anika Therapeutics executives and independent directors trade stock every 47 days with the average trade being worth of $613,258. The most recent stock trade was executed by Cheryl R Blanchard on 11 March 2024, trading 64,480 units of ANIK stock currently worth $1,563,640.

What does Anika Therapeutics do?

who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an

Complete history of Ms Nunes stock trades at Anika Therapeutics

Anika Therapeutics executives and stock owners

Anika Therapeutics executives and other stock owners filed with the SEC include:

• James Loerop,
  Executive Vice President - Business Development and Strategic Planning
• Thomas Finnerty,
  Executive Vice President of Human Resources
• Dr. Cheryl Renee Blanchard Ph.D.,
  Pres, CEO & Director
• David Colleran,
  Exec. VP, Gen. Counsel & Corp. Sec.
• James Loerop,
  Exec. VP of Bus. Devel. & Strategic Planning
• Michael L. Levitz,
  Exec. VP, CFO & Treasurer
• Thomas M. Finnerty,
  Exec. VP of HR
• Joseph Bower,
  Independent Chairman of the Board
• Jeffery Thompson,
  Independent Director
• Raymond Land,
  Independent Director
• Glenn Larsen,
  Independent Director
• Cheryl Blanchard,
  President, Chief Executive Officer, Director
• Susan Vogt,
  Independent Director
• Dr. Cheryl R. Blanchard,
  Pres, CEO & Director
• Stephen Richard,
  Independent Director
• John Henneman,
  Independent Director
• David Colleran,
  Executive Vice President, General Counsel, Secretary
• Michael Levitz,
  Chief Financial Officer, Executive Vice President, Treasurer
• Anne Nunes,
  VP of Operations
• Bart Bracy,
  VP of Sales & Marketing of Americas
• James Chase,
  Sr. VP of International Sales & Marketing
• Charles Sherwood III,
  VP & Corp. Legal Counsel
• Mark Namaroff,
  Exec. Director of Investor Relations & Corp. Communications
• Alexei Goraltchouk,
  Sr. VP of Operations & Project Management
• Richard Hague,
  Chief Commercial Officer
• Edward S. Ahn,
  Chief Tech. & Strategy Officer
• Charles H Sherwood,
  President and CEO
• Sylvia Cheung,
  Chief Financial Officer
• Steve E Wheeler,
  Director
• Dana M. Alexander,
  Chief Operations Officer
• Stephen R. Mascioli,
  Chief Medical Officer
• John C Moran,
  Director
• Joseph G Darling,
  President and CEO; Director
• Gary P Fischetti,
  Director
• Sheryl L Conley,
  Director
• John W Jr Sheets,
  Chief Scientific Officer
• Farmaceutici S.P.A. Fidia,
  10% owner
• Peter Litman,
  VP, Business Development
• William J Knight,
  Chief Financial Officer
• Harvey S Sadow,
  Director
• William Mrachek,
  V.P., Human Resources
• Samuel F Mckay,
  Director
• Eugene A Davidson,
  Director
• Francesco J Luppino,
  Chief Operating Officer
• Carol A Barnett,
  Chief Commercial Officer
• Kevin W Quinlan,
  Chief Financial Officer
• Constance H Garrison,
  VP Reg.,Clinical & Qlty. Sys.
• James E O Neill,
  Chief Accounting Officer
• Carol A Toth,
  Vice President, R & D
• Elizabeth Chen,
  Sr. VP Mktg. & Bus. Dev.
• Anne Nunes,
  SVP, Chief Operations Officer
• Stephen D. Griffin,
  EVP, CFO and Treasurer
• Joseph H Capper,
  Director
• William R Jellison,
  Director